Nomelcitinib (D-2570) vs WD-890
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
Nomelcitinib (D-2570)
Developed by InventisBio
NCT06278350 · Phase 2 · completed
The study randomized 161 participants with moderate to severe plaque psoriasis to three D-2570 dose groups or placebo, with participants, care providers and investigators masked. The primary endpoint, PASI 75 at week 12, was met in all three dose groups versus placebo (at least 85% vs 12.5%, p<0.001), per the sponsor's release and the peer-reviewed publication. The trial is mid-sized and 12 weeks long, so durability and safety beyond week 12 are not established.
Next expected readout: July 2027 · NCT07326813 (registry estimate)
Reported efficacy
Percentage of subjects with at least 75% improvement in PASI (Day 1-Day 85): Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001) (met)
Result source: NCT06278350
WD-890
Developed by Ningbo/Zhejiang Wenda Pharma Technology Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT07672561 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Nomelcitinib (D-2570) | WD-890 |
|---|---|---|
| PASI 75 | —Trial running · NCT07130604 | —Trial running · NCT07672561 |
| PASI 90 | —Trial running · NCT07130604 | —Trial running · NCT07672561 |
| PASI 100 | —Trial running · NCT07130604 | —Trial running · NCT07672561 |
| sPGA 0/1 | —Trial running · NCT07130604 | —Trial running · NCT07672561 |
| DLQI, change | —Trial running · NCT07130604 | —Trial running · NCT07672561 |
PASI 75
- Nomelcitinib (D-2570)
- —Trial running · NCT07130604
- WD-890
- —Trial running · NCT07672561
PASI 90
- Nomelcitinib (D-2570)
- —Trial running · NCT07130604
- WD-890
- —Trial running · NCT07672561
PASI 100
- Nomelcitinib (D-2570)
- —Trial running · NCT07130604
- WD-890
- —Trial running · NCT07672561
sPGA 0/1
- Nomelcitinib (D-2570)
- —Trial running · NCT07130604
- WD-890
- —Trial running · NCT07672561
DLQI, change
- Nomelcitinib (D-2570)
- —Trial running · NCT07130604
- WD-890
- —Trial running · NCT07672561
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
WD-890: no structured comparison results are available for Psoriasis.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nomelcitinib (D-2570)'s landscape · WD-890's landscape